Approval for new rheumatoid arthritis drug
NICE has recommended the use of the drug golimumab (Simponi) as an option for treating rheumatoid arthritis, in final guidance out today.
The drug should be used in specific circumstances where previous treatments have not worked.
Golimumab in combination with methotrexate is recommended for adults whose rheumatoid arthritis has responded inadequately to conventional disease-modifying antirheumatic drugs (DMARDs) only, including methotrexate.
In this case, golimumab is an option if it is used as described for other tumour necrosis factor (TNF) inhibitor treatments - adalimumab, etanercept and infliximab - covered by NICE technology appraisal 130, and the manufacturer provides the 100 mg dose of golimumab at the same cost as the 50 mg dose.
For adults whose rheumatoid arthritis has responded inadequately to other DMARDs, including a TNF inhibitor, golimumab in combination with methotrexate is also recommended as a treatment option.
In this situation golimumab can be used only as described for other TNF inhibitor treatments in NICE technology appraisal guidance 195 (which covers the use of adalimumab, etanercept, infliximab, rituximab and abatacept after the failure of a TNF inhibitor), andthe manufacturer provides the 100 mg dose of golimumab at the same cost as the 50 mg dose.
Dr Carole Longson, Health Technology Evaluation Centre Director at NICE said: “This final guidance sets out the circumstances where golimumab can now be offered by the NHS as a treatment option for people with rheumatoid arthritis for whom previous treatments have not worked.
“Rheumatoid arthritis treatments help to relieve pain, improve mobility and reduce the long-term damage often experienced by people with this condition.
“NICE has already recommended seven treatment options for patients living with this very disabling disease; now golimumab is another option.”
22 June 2011